Our in vitro effects counsel that EAM-2201 should be examined regarding prospective in vivo pharmacokinetic drug–drug interactions due to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 functions and competitive inhibition of UGT1A3 activity. This is a preview of subscription material, log in by way of an establishment to check https://salvadorv727jyo1.wizzardsblog.com/profile